HC Wainwright Reiterates “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $221.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 28.42% from the company’s previous close.

KRYS has been the topic of several other research reports. Chardan Capital reiterated a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $15.40 during trading on Wednesday, reaching $172.09. 258,675 shares of the company’s stock were exchanged, compared to its average volume of 237,902. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The company has a market cap of $4.95 billion, a P/E ratio of 97.01 and a beta of 0.84. The firm’s 50-day moving average price is $157.40 and its 200 day moving average price is $175.17.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Wednesday, February 19th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. As a group, equities research analysts predict that Krystal Biotech will post 3.22 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Krystal Biotech during the 4th quarter valued at $34,391,000. Soleus Capital Management L.P. increased its stake in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after buying an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC increased its stake in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after buying an additional 122,407 shares in the last quarter. State Street Corp increased its stake in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Krystal Biotech during the 4th quarter valued at about $15,989,000. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).